跳至主要内容
临床试验/IRCT20240115060698N1
IRCT20240115060698N1招募中3 期

The assessment of probiotics' effects on gastrointestinal inflammation and symptoms in patients with scleroderma

Mashhad University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
招募中
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20 years 至 65 years(—)
性别
All

入选标准

  • Diagnosis of scleroderma based on ACR-Eular criteria
  • Patients aged 20 to 65 years
  • Scleroderma patients with malabsorption symptoms such as bloating, bowel dysfunction, cyclic constipation and diarrhea, heartburn
  • If taking corticosteroids, they have not changed the dose of corticosteroids in the past month.

排除标准

  • Breastfeeding
  • Active infection
  • New organ involvement
  • Irritable bowel disease
  • Inflammatory bowel disease (IBD) and ulcerative colitis (UC)
  • Antibiotic intake in past 2 weeks
  • Probiotic intake in past 4 weeks
  • Endoxan in past 4 weeks
  • Rituximab in past 4 weeks
  • Biologic drugs in past 4 weeks
  • Medication changes in 2 month period of follow-up
  • Overlap syndromes
  • Voluntary withdrawal from the study

研究者

相似试验